Table 3.
Cross-sectional association of CBC phenotypes with brain MRI measures using linear mixed effect models. a
| Age >= 60 (n=1262) | Total sample (n=2713) | |||||||
|---|---|---|---|---|---|---|---|---|
| brain MRI measures b | CBC measures | Effect | 95% CI | p-value c | Effect d | 95% CI | p-value | |
| Primary outcomes | TCBV | NLR | −0.063 | (−0.18, 0.05) | 0.16 | −0.052 | (−0.14, 0.03) | 0.11 |
| RDW | −0.135 | (−0.28, 0.01) | 0.014 | −0.131 | (−0.23, −0.03) | 0.00098 | ||
| MPV | 0.113 | (−0.03, 0.25) | 0.035 | 0.069 | (−0.02, 0.16) | 0.058 | ||
| HPV | NLR | −0.000 | (−0.00, 0.00) | 0.71 | −0.000 | (−0.00, 0.00) | 0.71 | |
| RDW | −0.003 | (−0.01, 0.00) | 0.016 | −0.002 | (−0.01, 0.00) | 0.045 | ||
| MPV | 0.001 | (−0.00, 0.00) | 0.59 | 0.001 | (−0.00, 0.00) | 0.24 | ||
| WMH | NLR | 0.061 | (−0.01, 0.13) | 0.020 | 0.056 | (0.01, 0.10) | 0.0024 | |
| RDW | 0.059 | (−0.02, 0.14) | 0.058 | 0.018 | (−0.04, 0.08) | 0.43 | ||
| MPV | −0.017 | (−0.09, 0.06) | 0.57 | −0.030 | (−0.08, 0.02) | 0.14 | ||
| Secondary outcomes | CGV | NLR | −0.145 | (−0.25, −0.04) | 0.00030 | −0.143 | (−0.21, −0.07) | 0.0000003 |
| RDW | −0.125 | (−0.25, 0.00) | 0.011 | −0.133 | (−0.22, −0.04) | 0.00011 | ||
| MPV | 0.056 | (−0.07, 0.18) | 0.24 | 0.049 | (−0.03, 0.13) | 0.12 | ||
| FGV | NLR | −0.052 | (−0.10, −0.01) | 0.0047 | −0.058 | (−0.09, −0.02) | 0.000012 | |
| RDW | −0.034 | (−0.09, 0.02) | 0.13 | −0.037 | (−0.08, 0.01) | 0.024 | ||
| MPV | 0.011 | (−0.05, 0.07) | 0.63 | 0.019 | (−0.02, 0.06) | 0.21 | ||
| OGV | NLR | −0.022 | (−0.05, 0.00) | 0.032 | −0.026 | (−0.04, −0.01) | 0.00077 | |
| RDW | −0.014 | (−0.05, 0.02) | 0.27 | −0.020 | (−0.04, 0.00) | 0.036 | ||
| MPV | 0.022 | (−0.01, 0.05) | 0.079 | 0.014 | (−0.01, 0.04) | 0.100 | ||
| PGV | NLR | −0.047 | (−0.08, −0.02) | 0.000058 | −0.031 | (−0.05, −0.01) | 0.00020 | |
| RDW | −0.053 | (−0.09, −0.02) | 0.00019 | −0.043 | (−0.07, −0.02) | 0.000038 | ||
| MPV | 0.003 | (−0.03, 0.04) | 0.83 | 0.002 | (−0.02, 0.03) | 0.81 | ||
| TGV | NLR | −0.030 | (−0.07, 0.01) | 0.030 | −0.030 | (−0.06, −0.01) | 0.0013 | |
| RDW | −0.037 | (−0.08, 0.01) | 0.027 | −0.044 | (−0.07, −0.01) | 0.00018 | ||
| MPV | 0.030 | (−0.01, 0.07) | 0.064 | 0.023 | (−0.00, 0.05) | 0.030 | ||
CBC = complete blood count; CI = confidence interval; NLR = Neutrophil-to-lymphocyte ratio; RDW = red cell distribution width; MPV = mean platelet volume; TCBV = total cerebral brain volume; TCV = total intracranial volume; HPV = hippocampal volume; WMH = white matter hyperintensity; CGV = cerebrum gray matter volume; FGV = frontal gray matter volume; OGV = occipital gray matter volume; PGV = parietal gray matter volume; TGV = temporal gray matter volume; MRI = magnetic resonance imaging.
Model 1 covariates (age, age2, sex, ager-sex interaction, education level, cohort, time between blood draw and when the MRI measures were collected, prevalent CVD, C-reactive protein level, and APOE ε4 status) were included.
All brain MRI measures were computed as percentage of total intracranial volume. WMH was further log transformed.
p ≤ 0.01threshold to approximately account for multiple testing within the correlated MRI phenotypes.
The models for the age ≥ 60 (n=1313) subgroup and the total sample (n=2770) were fitted separately. The effect in the total sample without age interaction terms were reported. No age interaction is significant, so were not presented.